# Sichuan Baili Pharmaceutical Co., Ltd.: Phase 3 study closed enrollment, 515 enrolled (Urothelial Carcinoma)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Sichuan Baili Pharmaceutical Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) |
| NCT ID | NCT06857175 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Urothelial Carcinoma |
| Intervention types | drug |
| Target enrollment | 515 |
| Site countries | China |
| Posted | 2025-03-04 |
| Planned start | 2025-03-25 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-21 |
| Last update posted | 2026-10-21 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 515 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06857175). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.